1. Medicines
  2. Haematology
  3. REVOLADE® (eltrombopag olamine)
  4. Dosing

Prescribing information

 

REVOLADE: dosing

   

REVOLADE CAN OFFER CONVENIENT DOSE ADJUSTMENT WITH A FLEXIBLE STEP TITRATION1

REVOLADE is a once-daily, oral treatment available in 3 strengths: 25, 50 and 75 mg

Flow chart showing REVOLADE dosing

 

REVOLADE CAN HELP TO MEET YOUR PATIENTS' PREFERENCES

In the global I-WISh survey,2,3 ITP patients were asked, "Please select your preference in terms of how you would like to take your ITP medicine if you had a choice".3§

  • 84% of patients chose a once-daily oral treatment over an injection or a twice-daily oral regimen3|¶
Pie chart depicting patient formulation preference
 

 

REVOLADE CAN FREE PATIENTS FROM INJECTIONS WITH THE CONVENIENCE OF A ONCE-DAILY ORAL TABLET2,3

  • In one study 31% (11/35)4** of patients on romiplostim were switched to eltrombopag due to platelet fluctuation and and for 55% (6/11)4 patients this strategy was effective
  • In another study 8 patients that switched TPO-RA due to patient preference, none switched from REVOLADE to romiplostim5††
  • REVOLADE is easy to administer and can provide the CONVENIENCE of a once-daily oral tablet1,6
Table of data highlighting REVOLADEs convenience
 

* For patients taking 25 mg eltrombopag once every other day, increase dose to 25 mg once daily. †For patients taking 25 mg eltrombopag once daily, consideration should be given to dosing at 12.5 mg once daily or alternatively a dose of 25 mg once every other day. ‡Restart REVOLADE at a lower dose when the platelet count is ≤100,000/μL. §Results are based on responses of 1,491 patients involved in a patient and physician survey on ITP conducted in 13 countries. |Alternate dosing schedule approved in the label, with effective cycle dosing proven in clinical trials. Patients did not show a preference for a specific product and may or may not have had experience with any therapeutic option for ITP. **Based on an analysis of TPO-RA switching studies evaluating a total of 178 patients. ††Based on an analysis of TPO-RA switching study evaluating a total of 106 patients.

Abbreviations: BID, twice-daily; ITP, immune thrombocytopenia; OD, once daily; TPO-RA, thrombopoietin-receptor agonist.

References

  1. REVOLADE Summary of Product Characteristics.
  2. Kruse A, et al. Presented at EHA 24th Annual Congress, Amsterdam, Netherlands, June 13–16, 2019. PF711.
  3. Data on file. I-WISh global study page 55 (REVDOF001).
  4. Khellaf M, et al. Haematologica. 2013;98(6):881–887.
  5. Cantoni S, et al. Am J Hematol. 2018;93:58–64
  6. Witticke D, et al. Patient Preference and Adherence. 2012;6:679–684.
HCP19-C002h(1) June 2020.
Haematology
Article
Print

For more information, refer to the REVOLADE® (eltrombopag olamine) Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/7819/smpc

Legal Category: POM.

Aluminium blisters (PA/Alu/PVC/Alu) in a carton containing 14 or 28 film-coated tablets and multipacks containing 84 (3 packs of 28) film-coated tablets. Marketing Authorisation (MA) number, quantities and NHS price: EU/1/10/612/002 – 25 mg x 28 tablet pack £770, EU/1/10/612/005 – 50 mg x 28 tablet pack £1540, EU/1/10/612/008 – 75 mg x 28 tablet pack £2310

 

×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]